The ability to selectively and safely target causative pathogens represents a novel approach to the prevention of infections in high-risk patients, providing clinical and health economic benefits to patients and ushering in a new era in infection management.
We believe that targeted prevention fills an important middle ground between traditional prophylactic efforts (through vaccines) and post-infection treatment (through antibiotics) of bacterial diseases. Our vision is to identify high-risk patients colonized with a specific pathogen, and then work to maintain their immune response by interrupting bacterial pathogenesis processes that disrupt it.
Targeted prevention could profoundly impact patient outcomes and healthcare spending. This approach would provide healthcare providers with new options to proactively reduce infections in acute care settings and lessen the downstream need for multiple antibiotic courses that contribute to resistance, toxicity, and subsequent infections. Targeted prevention of infection could also reduce mechanical ventilation days, shorten hospital stays, reduce healthcare costs, and decrease the risk of re-hospitalization.